Every 10-Q that Silence Therapeutics Plc (SLN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SLN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLN filings page.
Silence Therapeutics plc reported interim results for the three and six months ended June 30, 2026, highlighting a smaller loss and reduced cash burn while advancing its RNAi pipeline. For the six-month period, revenue was $0.4 million from its AstraZeneca collaboration, unchanged versus 2025. The company remains precommercial.
The net loss for the six months was $27.2 million, about half the prior-year loss of $55.9 million, driven mainly by sharply lower research and development spending following completion of zerlasiran Phase 3 readiness activities. Research and development costs fell to $18.3 million from $38.5 million, and general and administrative expenses also decreased modestly.
Cash flow from operations improved to an outflow of $14.1 million from $34.1 million, helped by a $14.2 million receipt of U.K. R&D tax credits. Silence ended June 30, 2026 with $72.1 million in cash and cash equivalents and believes this will fund forecasted operating and capital needs into 2028, though additional capital will be required to support broader clinical development. The accumulated deficit reached $589.6 million, underscoring ongoing dependence on external funding and collaboration income, including a large $55.2 million AstraZeneca-related contract liability to be recognized as future revenue.
Silence Therapeutics plc reported a smaller net loss for the three months ended March 31, 2026 as it advanced its RNAi pipeline and absorbed changes in a key collaboration. Revenue from its AstraZeneca alliance was $0.4 million, up from $0.1 million a year earlier.
Research and development costs fell to $9.1 million from $20.8 million, mainly as Phase 3 readiness work for zerlasiran wound down and headcount declined. Net loss narrowed to $15.0 million (loss per share $0.11) from $28.5 million (loss per share $0.20).
Cash, cash equivalents and short-term investments totaled $70.1 million, and the company believes this will fund operations into 2028, though additional capital will be needed for later-stage development. AstraZeneca decided not to develop SLN312 beyond Phase 1, and Silence will regain full global rights while evaluating further clinical plans. Lead asset divesiran is in a fully enrolled Phase 2 PV trial with topline data expected in the third quarter of 2026, and zerlasiran is Phase 3 ready as the company seeks a partner.
Silence Therapeutics plc reported third‑quarter results reflecting lower collaboration revenue and ongoing R&D investment. Revenue was $159 thousand in Q3 2025 versus $1.498 million a year ago, mainly due to fewer recognized AstraZeneca milestones. Net loss was $20.958 million (vs. $35.544 million), with operating expenses of $20.544 million in R&D and $5.795 million in G&A.
For the first nine months, revenue was $525 thousand (vs. $17.953 million) and net loss was $76.842 million (vs. $57.611 million). Cash, cash equivalents and short‑term investments totaled $102.2 million as of September 30, 2025, and management believes existing liquidity and anticipated collaboration milestones can fund operations into 2028. Contract liabilities tied to the AstraZeneca collaboration were $55.552 million, to be recognized over future periods.
Pipeline updates note divesiran (SLN124) Phase 2 SANRECO enrollment completed in October 2025, with initial topline results anticipated in the third quarter of 2026. Zerlasiran (SLN360) completed Phase 3 readiness activities, with partnering sought for Phase 3 and potential commercialization. Shares outstanding were 141,701,848 as of October 30, 2025.